Biodexa Shareholders Greenlight 1-for-10,000 Reverse Split and £25M Share Issuance Authority
BDRX sits 50% above its 52-week low of $1.02.
Summary
Biodexa shareholders approved a 1-for-10,000 reverse stock split and authorized the board to issue up to £25 million in new shares, setting the stage for further dilution to fund operations.
Key Events · Corporate Governance and Compliance · BDRX
-
Reverse Stock Split Approved
Shareholders approved a 1-for-10,000 reverse stock split, effective July 30, 2026, reversing the earlier rejection on June 30, 2026. Post-split, there will be 51.5 million ordinary shares outstanding, equivalent to 1.03 million ADSs.
-
£25 Million Share Issuance Authority
The board was authorized to allot up to £25 million (~$32 million) in new shares on a non-pre-emptive basis through the 2029 annual general meeting. This represents potential dilution many times the company's current market cap.
-
ADS Ratio Change
The ADS ratio changes from 1 ADS per 500,000 ordinary shares to 1 ADS per 50 ordinary shares, effective July 30, 2026. This does not alter proportional ownership but adjusts the ADS structure to reflect the reverse split.
-
Nasdaq Compliance Strategy
The reverse split is intended to raise the per-share price to meet Nasdaq's minimum bid price requirement, addressing a listing deficiency. However, the newly authorized share issuance authority signals that further dilutive financings are likely.
Analysis · BDRX · Life Sciences
In a sharp reversal from their earlier stance, Biodexa shareholders approved a 1-for-10,000 reverse stock split, effective July 30, 2026. The vote also grants the board authority to issue up to £25 million in new shares through 2029 — a massive potential dilution for a company with a market cap of only ~$650,000. While the reverse split is designed to cure the company's Nasdaq listing deficiency, the newly authorized share issuance authority, combined with the company's recent history of highly dilutive financings, signals that significant additional dilution is likely. The post-split share count will be 51.5 million ordinary shares, equivalent to 1.03 million ADSs, with the ADS ratio changing from 500,000:1 to 50:1.
At the time of this filing, BDRX was trading at $1.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $650.4K. The 52-week trading range was $1.02 to $59.40. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.